SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
New Stock Indexes to Track Trends in Healthcare Sector
TEVA
|
|
|
+4.52%
in
12 days
Coming Soon. . . a premium service offered in collaboration with Investars YOU for full access to a global database of over 1,000 stocks which are organized and managed within my 20 ProActive HavRx stock indexes . The expected pricing for premium access is $60 per year and will include full access to all of the component stocks in the indexes and tracking data for the indexes. <> Emerging Cancer Diagnostic / Therapeutic (Dx / Tx) Index
The actively managed HavRx Emerging Cancer Dx / Tx Index constituents reflect a cross-section of emerging cancer companies with <><><><><><><><><><><><><><><><><><><>< />< /><><>< />< /><><>< />< />< />< /><><>< />< /><><>< />< /><><>< />< /><><><><><><><><><><>< />< /><><>< />< />< />< /><><>< />< /><><>< />< /><><>< />< />< />< /><><>< />< />< />< /><><>< />< />< />< /><><>< />< /><><><><><><><><><>...
|
FDA, Clinical Trial Calendar Updates: THRX, GILD, TEVA, ALNY, RNUGF
TEVA
|
|
|
+10.50%
in
205 days
(closed on 10/28/09)
The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 112 entries through 4/6/09. The FDA Calendar includes the following information: company name, ticker, decision date, and description. <> The Clinical Trial Calen...
|
Momenta Pharma's Three-Part Strategy
TEVA
|
|
|
+1.69%
in
31 days
(closed on 04/06/09)
Momenta Pharma (MNTA) is pursuing a three-part business model which includes complex generic equivalents in partnership with the Sandoz division of Novartis (NVS), proprietary compounds, and follow-on- biologics (FOB). <> Momenta is partnered with Sandoz to develop a generic equivalent (M-Enoxaparin) of the multi-billion dollar injectable blood thinner Lovenox ($3.9B in worldwide sales for 2008). While MNTA + NVS were not the first to file for a generic version of Lovenox, the 180-day exclusivity period awarded to the first-to-file company is set to expire on 4/1/09 for Amphasta...
|
Big Pharma Goes Generic
TEVA
|
|
|
-1.84%
in
8 days
(closed on 03/06/09)
<> <> <> <> <> <>  Sanofi-Aventis (SNY) is now the 11 th largest generic drug maker in the world following its successful acquisition of Czech generic drug company Zentiva. As $70B in brand drug patents are set to expire through 2012, big pharma companies are hedging their bets through generic drug divisions, including Pfizer (PFE) - Greenstone, Novartis (NVS) - Sandoz, and the recently announced Merck (MRK) BioVent...
|
Caraco Pharma Awaits FDA Inspection in May
TEVA
|
|
|
-0.09%
in
20 hours
(closed on 02/26/09)
By Mike Havrilla on 2/25/09 I spoke with the investor relations representative for Caraco Pharma (CPD) earlier this week and received some clarity on the expected timeline for resolving the major overhang on the stock price related to the FDA warning letter over Form 483 concerns by the agency stemming from quality control issues raised during an inspection of manufacturing facilities last year. <> Caraco has responded in full to the warning letter and the FDA will evaluate the corrective actions taken by the Company at its next s...
|
From the Blogosphere
Zacks Analyst Blog Highlights: Baker Hughes Inc., BJ Services, Teva Pharmaceutical Industries Ltd., Mylan and Comcast Corp. – Press Releases
|
|
|
For Immediate Release Chicago, IL – November 5, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Baker Hughes Inc. (BHI), BJ Services (BJS), Teva Pharmaceutical Industries Ltd. (TEVA), Mylan (MYL) and Comcast Corp. (CMCSA). Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513 <><>Here are highlights from Wednesday’s Analyst<><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>< />< />< />< /><><><><>< /><><>< /><>< /><>< />< />...
|
Teva Reports Strong Quarter – Analyst Blog
|
|
|
Teva Pharmaceutical Industries Ltd. (TEVA) reported earnings of 89 cents in the third quarter of 2009, up 16% from the year-ago period and a cent above the Zacks Consensus Estimate. Strong sales of Copaxone and in the respiratory business helped drive earnings in the reported quarter.
Net sales increased 25% to $3.55 billion, with the Barr acquisition contributing to sales across different geographical segments. The strengthening U.S. dollar adversely impacted net sales by $160 million or 6%.
Revenue performance across key business segments was mixed. While the Pharmaceuticals Sales segment p...
|
The week in preview: Eye on MasterCard, Prudential, Coinstar ...
Teva (TEVA): Baby-boomers give boost to generics
TEVA
+2.60%
in
26 days
Filed under: International markets, Newsletters, Teva Pharm Indus ADR (TEVA), Stocks to Buy, Israel, Obama Picks  "The health care picks in our growth portfolio should prosper whatever the outcome of the raging health care debate," suggests growth stock specialist Stephen Leeb.
In The Complete Investor, he explains, "That's because they're leveraged to demographic realities, and in particular to the tide of aging baby boomers," Here, he reviews on portfolio holding -- Teva Pharmaceuticals (NASDAQ: TEVA). <>Leeb says, "Israel-based Teva Pharmaceutical is the world's largest manufacturer of generic...
|
Teva (TEVA): Baby-boomers boost generics
|
|
|
 "The health care picks in our growth portfolio should prosper whatever the outcome of the raging health care debate," suggests Stephen Leeb.
In The Complete Investor, he explains, "That's because they’re leveraged to demographic realities, and in particular to the tide of aging baby boomers," Here, he reviews on portfolio holding -- Teva Pharmaceuticals (NASDAQ: TEVA). "Israel-based Teva Pharmaceutical is the world’s largest manufacturer of generic drugs. <>"Capitalized at $49 billion, Teva pulled in some $11 billion in revenues in 2008, with generic drugs contributing more than two-thirds ...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on TEVA |
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About Teva Pharmaceutical Industries Ltd
- Answers.com
It's official: the holiday season is here, marking the beginning of the race to the end of the year. It's also time for another 
